JP2021527656A5 - - Google Patents

Info

Publication number
JP2021527656A5
JP2021527656A5 JP2020570444A JP2020570444A JP2021527656A5 JP 2021527656 A5 JP2021527656 A5 JP 2021527656A5 JP 2020570444 A JP2020570444 A JP 2020570444A JP 2020570444 A JP2020570444 A JP 2020570444A JP 2021527656 A5 JP2021527656 A5 JP 2021527656A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
identity
progranulin
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527656A (ja
JP7517997B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037695 external-priority patent/WO2019246071A1/en
Publication of JP2021527656A publication Critical patent/JP2021527656A/ja
Publication of JP2021527656A5 publication Critical patent/JP2021527656A5/ja
Application granted granted Critical
Publication of JP7517997B2 publication Critical patent/JP7517997B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570444A 2018-06-18 2019-06-18 プログラニュリンを含む融合タンパク質 Active JP7517997B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862686579P 2018-06-18 2018-06-18
US62/686,579 2018-06-18
US201862746338P 2018-10-16 2018-10-16
US62/746,338 2018-10-16
PCT/US2019/037695 WO2019246071A1 (en) 2018-06-18 2019-06-18 Fusion proteins comprising progranulin

Publications (3)

Publication Number Publication Date
JP2021527656A JP2021527656A (ja) 2021-10-14
JP2021527656A5 true JP2021527656A5 (cg-RX-API-DMAC7.html) 2022-06-27
JP7517997B2 JP7517997B2 (ja) 2024-07-17

Family

ID=67138158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570444A Active JP7517997B2 (ja) 2018-06-18 2019-06-18 プログラニュリンを含む融合タンパク質

Country Status (17)

Country Link
US (3) US20210284702A1 (cg-RX-API-DMAC7.html)
EP (1) EP3807322A1 (cg-RX-API-DMAC7.html)
JP (1) JP7517997B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210027377A (cg-RX-API-DMAC7.html)
CN (1) CN112424233A (cg-RX-API-DMAC7.html)
AU (1) AU2019288212B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025306A2 (cg-RX-API-DMAC7.html)
CA (1) CA3101202A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003255A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20081591A (cg-RX-API-DMAC7.html)
IL (1) IL279510B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020012518A (cg-RX-API-DMAC7.html)
PE (1) PE20210323A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552189A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011743SA (cg-RX-API-DMAC7.html)
TW (1) TWI874321B (cg-RX-API-DMAC7.html)
WO (1) WO2019246071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
AU2016270587B2 (en) * 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
US20210396772A1 (en) * 2018-10-16 2021-12-23 Denali Therapeutics Inc. Methods for treating and monitoring progranulin-associated disorders
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) * 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN116133684B (zh) * 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
US20210393787A1 (en) * 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
KR102666958B1 (ko) * 2020-09-18 2024-05-23 한양대학교 산학협력단 PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물
EP4215607A4 (en) * 2020-09-18 2024-11-06 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) Ptpsigma-fc fusion protein and pharmaceutical composition comprising same
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
EP4229419A2 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
AR128003A1 (es) * 2021-12-17 2024-03-20 Denali Therapeutics Inc PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS
WO2023198661A1 (en) * 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
CN119213030A (zh) * 2022-05-16 2024-12-27 戴纳立制药公司 转铁蛋白受体结合结构域和包含其的蛋白
JP2024037109A (ja) * 2022-09-06 2024-03-18 国立大学法人九州大学 分析容器、前処理方法、代謝物解析方法、タンパク質解析方法、及び質量分析方法
EP4630030A2 (en) * 2022-12-06 2025-10-15 ProteinQure Inc. Targeting sortilin
EP4731669A2 (en) * 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier
WO2025051953A1 (en) * 2023-09-07 2025-03-13 Novo Nordisk A/S Sortilin-1 binders, constructs and uses thereof
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
WO2025166077A1 (en) * 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
EP4755905A1 (en) 2024-12-05 2026-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Truncated progranulin protein and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3991748A3 (en) * 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
AU2016282334B2 (en) * 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
WO2018024162A1 (en) * 2016-08-03 2018-02-08 Sunshine Lake Pharma Co., Ltd. Glp-1 fusion protein comprising mutated immunoglobulin fc portion
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models

Similar Documents

Publication Publication Date Title
JP7397063B2 (ja) 操作された二重特異性タンパク質
KR102514330B1 (ko) Pd-1 및 lag-3와의 면역반응성을 가진 공유 결합된 디아바디, 및 그것의 사용 방법
JP6744856B2 (ja) α−シヌクレインを認識する抗体を含む血液脳関門シャトル
ES2749457T3 (es) Anticuerpos humanizados que reconocen la alfa-sinucleína
JP2023512450A5 (cg-RX-API-DMAC7.html)
JP2021533779A5 (cg-RX-API-DMAC7.html)
KR20190134997A (ko) 항-tau 항체 및 이의 사용 방법
EP2985294A1 (en) Recombinant antibody molecule and its use for target cell restricted T cell activation
JP2021534220A5 (cg-RX-API-DMAC7.html)
KR102884943B1 (ko) 개선된 항-flt3 항원 결합 단백질
US20210070881A1 (en) Anti-bace1 antibodies and methods of use thereof
CN109963869A (zh) 与经改造的Fc构建体相关的组合物和方法
US12473369B2 (en) Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatment
JP2023545707A5 (cg-RX-API-DMAC7.html)
US20240279324A1 (en) Multispecific antagonists
JP2022530068A5 (cg-RX-API-DMAC7.html)
TH2001007134A (th) ฟิวชันโปรตีนซึ่งประกอบรวมด้วยโพรแกรนูลิน
KR20230123923A (ko) 항-EphA4 항체
JP2021510162A5 (cg-RX-API-DMAC7.html)
CA3111462C (en) Improved anti-flt3 antigen binding proteins
US20230391880A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
KR20230118573A (ko) 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도